SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) ($DOG.X) is trending as the community rallies around its status as the premier memecoin on the Bitcoin network, emphasizing its fair launch and decentralized nature. Discussions highlight its potential for significant growth within the Bitcoin ecosystem, with many considering it a key to onboarding new users. The community emphasizes the absence of insiders and VC involvement, promoting it as a truly community-driven project.

DMTC or DIAMOND The Cat Coin is a viral meme coin on Solana Blockchain, Based in Thailand and Global and Based on a true story about my lovely cat(DIAMOND) and made by love, I just want my cat to be immortal in this whole world until I die that's a first idea of this project start. We're start from $2,000 Market cap and hit All time high at $10.9 million, please come to check our project and let's DMTC get list on Coingecko to let's everyone in this whole world know DMTC.

DIAMOND The Cat Coin

Diamond The Cat Coin ($DMTC.X) is trending as the community anticipates a potential breakout, with many noting positive chart signals and building momentum. Discussions revolve around key technical levels and upcoming catalysts, while some compare $DMTC.X to similar projects in the broader market.

Deng Deng, a Shiba Inu abandoned in China, was sold at an online auction in Beijing in November 2021 for 160,000 yuan (approximately $25,000 USD).  Deng Deng’s viral story on Weibo, detailing his abandonment at a pet training center in 2014, drove the high price, amplified by the rising popularity of Shiba Inus linked to cryptocurrencies like Dogecoin. Stay up-to-date with the latest DENG DENG memes, updates, and community events. Be part of the most expensive Shiba Inu community!

The Most Expensive Shiba Inu

DENGDENG.X is trending as investors discuss potential entry points and long-term vision, while some community members suggest the chart is consolidating before a potential breakout. Traders are also comparing it to other cryptos like BTC.X and SOL.X.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies behind its unique meme-driven approach, combining humor with charitable donations to dog shelters. Built on Solana, UpDog is focused on community growth and spreading the word. Many are drawn to the project's longevity and pioneering spirit within the joke meta.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members highlight significant institutional accumulation and inflows into Solana ETFs, sparking discussions about its potential to reach new milestones. A wave of new memecoins on the Solana blockchain, like $WAGMI.X, $UPDOG.X and $AINAL.X, are also driving interest and community engagement. Some are comparing Solana to early Ethereum, anticipating substantial growth.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining is trending as investors discuss the company's potential amidst fluctuating gold prices and recent earnings reports. Community members are debating the impact of new mining projects, like Bilboes, on future production and profitability, while comparing CMCL's growth and dividend yield to other companies like Nvidia. Some investors believe CMCL is undervalued given its assets and potential in the current gold market, while others express concern about political risks and operational stability in Zimbabwe.

What is the project about?  BobaCat (PSPS) is a cryptocurrency token created as an homage to Boba Cat, the adopted cat of Dogecoin co-founder Billy Marcus.  What makes your project unique?  Transparency At BobaCat, we're all about being open and honest. We believe that sharing clear information about what we do is what brings our crypto community together and makes it strong.  History of your project.  BobaCat has recently transitioned to the Ethereum (ETH) network from its previous presence on the Binance Smart Chain (BSC). During this migration, the project has forged several meaningful partnerships with select pet shelters, bolstering its commitment to animal welfare. In addition, BobaCat has cultivated a vibrant and engaged community of supporters, and it has successfully established itself as a legally recognized non-profit organization.  What’s next for your project?  Our mission is to educate non-profit societies to adopt cryptocurrencies and blockchain technology to bring more transparency, reduce transaction costs, and remove third parties.  What can your token be used for?  Governance: Token holders can participate in governance decisions, helping shape the future of the project, such as voting on proposals for partnerships, projects, or changes to the platform. BobaCat DAO: https://snapshot.org/#/bobainu.eth  Utility: The token can be used for various utilities within the platform, like accessing premium features, exclusive content, or participating in special events and promotions.  Charitable Contributions: As a non-profit organization, BobaCat may accept donations in the form of its native token, allowing users to contribute to animal welfare causes.  Trading: The token can also be traded on various cryptocurrency exchanges, providing liquidity and the potential for investment gains.

BobaCat

BobaCat is trending due to its upcoming migration to the new BOBA token, which the community believes will increase visibility and broaden its appeal within the crypto space. Discussions also highlight the project's philanthropic efforts, inspired by Dogecoin's founder's cat, Boba, and its commitment to helping animal shelters, creating a strong narrative for the meme coin.

Pump.fun

Pump.fun ($PUMP.X) is trending as the community highlights its potential within the meme coin space on Solana, with some suggesting it's the next big mover. Bullish sentiment is fueled by discussions around staking and community-driven initiatives. There is also speculation around future exchange listings.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as the community discusses its potential for significant gains, drawing comparisons to other successful cryptocurrencies. The recent price action and backing from major players are fueling speculation about a run toward $1 and beyond. Traders are closely watching for consolidation and accumulation patterns, anticipating further upward movement.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM.X) is trending as traders discuss potential price movements and accumulation strategies, with some anticipating a significant pump. Community members are closely watching for whale activity and key resistance levels, speculating on the potential impact of AI developments and a possible Binance listing. The conversation includes both bullish sentiment and caution, as traders weigh the risks and opportunities associated with this altcoin.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects

Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

Merck (MRK) concluded the recent trading session at $85.11, signifying a +1.28% move from its prior day's close.

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? 

Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.

U.S. stocks closed Wednesday’s session mixed, with the broader S&amp;P 500 Index and the Nasdaq Composite hitting fresh highs, while the Dow Jones Industrial Average retreated.Although the tame producer price inflation report generated some strength in the market in the morning session, the perils of trading an overbought market made traders cautious as the session progressed.The following stocks saw the biggest volume surge in extended trading, even as the market turns its attention to the August consumer price inflation CPI) report due on Thursday:SLB Ltd. (SLB)After-hours move: 0.14%Trading volume: 5.86 millionOilfield services company SLB remained on investors’ radar despite the lack of any significant news. The Houston, Texas-based company’s shares rose over 1% on Wednesday, outperforming the broader market, after crude oil futures climbed 1.7% during the session.&nbsp;The stock, however, is down 3.5% for the year-to-date period.<figure class="image"><img style="aspect-ratio:618/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_40_24_AM_png_ff671b9818.webp" alt="Screenshot 2025-09-11 at 12.40.24 AM.png" width="618" height="54"><figcaption>SLB sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/SLB">SLB stock</a> remained ‘neutral’ (51/100) by late Wednesday, and the message volume also stayed ‘normal.’Apple, Inc. (APPL)After-hours move: +0.10%Trading volume: 4.67 millionApple’s stock tumbled over 3% on Wednesday, even as the broader market managed to close in the green. The drop came despite the stock snagging a slew of price target hikes from Wall Street firms following the “Awe Dropping” hardware launch event held on Tuesday.BofA, Rosenblatt, Melius Research and Evercore ISI were among the firms that upped their price targets for Apple’s stock, with the updated estimates from these firms ranging from $241 to $290, the Fly reported. JPMorgan and Citi said the launch event was aligned with their expectations, while Morgan Stanley said it was slightly more awe-dropping than expectations.<a href="https://stocktwits.com/symbol/AAPL">Apple stock</a> is down about 9.1% year-to-date (YTD).<figure class="image"><img style="aspect-ratio:615/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_42_11_AM_png_38eba34d1f.webp" alt="Screenshot 2025-09-11 at 12.42.11 AM.png" width="615" height="58"><figcaption>AAPL sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>Retail sentiment toward the stock remained ‘extremely bullish’ (85/100), and the message volume was ‘extremely high.’&nbsp;Nvidia Corp. (NVDA)After-hours move: -0.10%Trading volume: 4.21 millionNvidia rode on the back of Oracle's (ORCL) exuberance and ended Wednesday’s session up nearly 5% at $177.33, although it was off its all-time intraday high of $184.48. However, retail interest is on the wane. On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/NVDA">Nvidia stock</a> remained ‘bearish’ (37/100). The message volume on the stream was ‘low’ relative to historical norms.<figure class="image"><img style="aspect-ratio:622/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_43_57_AM_png_ec461b54d9.webp" alt="Screenshot 2025-09-11 at 12.43.57 AM.png" width="622" height="59"><figcaption>NVDA sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>The shares of the artificial intelligence chipmaker are up more than 32% this year.Merck &amp; Co. (MRK)After-hours move: +0.10%Trading volume: 3.91 millionPharma giant Merck has come onto investors’ radar as it declined on Wednesday, aligning with the pullback in the healthcare stocks in the afternoon. The S&amp;P 500 Healthcare Index fell 0.91% on Wednesday.The company also abandoned plans to build a research center in the U.K., citing the “challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments,” the London Times&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thetimes.com/business-money/companies/article/merck-attacks-uk-life-sciences-investment-scraps-1bn-hq-jbzz9nmnb">reported.</a><figure class="image"><img style="aspect-ratio:620/50;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_45_04_AM_png_6aeae81193.webp" alt="Screenshot 2025-09-11 at 12.45.04 AM.png" width="620" height="50"><figcaption>MRK sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/MRK">Merck stock</a>, which has fallen nearly 14% this year, elicited ‘bearish’ sentiment (42/100) from among users on Stocktwits. The message volume was at ‘normal’ levels.Gilead Sciences, Inc. (GILD)After-hours move: +0.65%Trading volume: 3.57 millionGildead Sciences was in the news on Wednesday as RBC Capital Markets named the company as one of the beneficiaries of Health and Human Services (HHS) Secretary and prominent antivaxxer Robert Kennedy's potential departure from the agency.&nbsp;The firm said healthcare could be viewed as "less unpredictable" and "more investable" if the secretary were to depart his position, according to the Fly.Kennedy has been under pressure from HHS employees, both former and current, to quit, as they alleged that he has put the health of America at risk with his actions, which include cancelling emergency use authorizations for COVID-19 vaccines without providing data or methods to justify the decision.<figure class="image"><img style="aspect-ratio:616/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_46_18_AM_png_9b7d1d480e.webp" alt="Screenshot 2025-09-11 at 12.46.18 AM.png" width="616" height="53"><figcaption>GILD sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/GILD">Gilead Sciences stock</a> remained ‘neutral’ (47/100). and the message volume also stayed at ‘normal’ levels.The stock has gained 26.5% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-ceo-sees-25-bps-fed-rate-cut-as-done-deal/chwN5NiRdH4">Will Fed Cut Rates Next Week? What Goldman Sachs CEO David Solomon Predicts For September Meeting And Rest Of 2025</a>

Traders work on the floor of the New York Stock Exchange (NYSE) on July 30, 2025, in New York City. 

SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?

Two stocks, each from the tech and healthcare sectors, experienced brisk trading activity in the post-market session on Wednesday, although volumes were relatively muted.

Equity

Two stocks, each from the tech and healthcare sectors, experienced brisk trading activity in the post-market session on Wednesday, although volumes were relatively muted.


Merck (MRK) has reportedly scrapped a £1 billion ($1.35 billion) London research centre and intends to lay off over 100 scientific staff in the U.K.The Financial Times <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/5ace49a8-47ab-409d-8909-6edb107ce71a">reported </a>on Wednesday that the drugmaker scrapped the research centre in King’s Cross, which was due to open in 2027, and instead would move research activity to existing sites, predominantly in the U.S. The company committed to the research centre focused on neuroscience, inflammation, and immunology in King’s Cross in 2017, and construction commenced in 2023, FT said.Merck would also lay off 125 scientists and support staff who had been working on early discovery efforts at the Francis Crick Institute and the London Bioscience Innovation Centre, according to the report.However, the company will continue to run clinical trials in the country and will have about 1,600 staff working on these development programs and other areas, the report said. Merck told FT in a statement that the U.K. is “not internationally competitive.”The decision comes on the heels of a battle between drug makers and the U.K. Health Secretary Wes Streeting on medicine prices. However, Merck told FT that its decision to scrap the London research centre was not related to the drug-pricing negotiations with the government.The company, however, stated that the U.K. would lag behind its European peers in the share of the health budget allocated to drugs unless it improved its ability to attract and retain investment, according to the FT.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRK">MRK stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_at_12_15_49_PM_png_73cef3623f.webp" alt="MRK's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Sept. 10, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>MRK's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Sept. 10, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expects the stock to reach $97.50, implying a reasonable upside from its current trading levels.<stembedurl>https://stocktwits.com/wilpd/message/628089752</stembedurl>Meanwhile, in the United States, Merck <a href="https://stocktwits.com/news-articles/markets/equity/trump-to-issue-60-day-warning-letters-to-drugmakers-over-pricing/choL0IMRdGB">faces</a> a September-end deadline to reduce the cost of its medicines as Trump pushes drugmakers to lower the cost of drugs in the U.S. to the levels paid by other developed nations.According to data from Koyfin, 15 of the 37 analysts covering Merck rate it ‘Buy’ or higher, while 12 rate it ‘Hold’. The average price target for the stock is $102.33, representing an upside of over 22%.MRK stock is down by 16% this year and by 27% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-analyst-expects-tesla-q3-deliveries-to-fall-below-consensus-estimate/chwkig8RduAhttps://stocktwits.com/news-articles/markets/equity/wells-fargo-analyst-expects-tesla-q3-deliveries-to-fall-below-consensus-estimate/chwkig8RduA">This Analyst Expects Tesla Q3 Deliveries To Fall Below Consensus Estimates: Retail Sees Rally To $400 After Next Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50 

The Financial Times reported on Wednesday that the drugmaker scrapped the research centre in King’s Cross, which was due to open in 2027, and will instead move research activity to existing sites. 

J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum

J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.

Will LLY's Oncology Portfolio Provide Key Diversification Benefits?

Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Current Price	$83.17
Prev Close	$85.15
Open	$84.62
Dividend Yield	3.14%
50-Day Moving Average	$82.84
Beta	0.30
Avg. Volume	10.98M
PE Ratio	12.77

52-Week High	$119.38
52-Week Low	$73.31
Market Capitalization	$206.84B
EPS (Annual)	$6.74
Price to Book	4.23
Revenue Per Employee	$852,973.33
Enterprise Value/EBITDA	N/A

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRK News

MRK Merck & Co Inc